Drug Discovery
ByMerck’s First Fully AI-Designed Oncology Drug: 2027 China Approval Nears or Hype Peaks?
Merck’s January 26–March 2026 trajectory signals China will approve its first fully AI-designed compound by 2027—the world’s first…
China’s $2-3B AI Healthcare Pilots Launch: Rural Revolution or Data Control Play?
China’s National Health Commission launched pilots March 1-3, 2026, under its CNY 15-20B ($2-3B) AI strategy—rolling out AI…
NVIDIA Survey: 70% US Healthcare AI Adoption—Efficiency Lifeline or Insider Breach Timebomb?
NVIDIA’s March 1 survey shows 70% of US healthcare organizations now use AI, mainly to save time on…
Qure.ai Secures Landmark FDA Clearance for qXR-Detect, Cementing AI Leadership in Global Diagnostics—Brainlab Partnership Signals Agentic AI Workflow Revolution
Mumbai, India – March 4, 2026 – Qure.ai, a global leader in AI-powered radiology, today celebrated FDA clearance for…
How Does Johnson & Johnson Weaponize Oncology Supremacy for $50 Billion Revenue by 2030?
Johnson & Johnson orchestrates a “full-spectrum oncology domination” strategy across its Innovative Medicine division, positioning for #1 global oncology leadership…
How Does Pfizer Transform Oncology Supremacy Into Sustainable Growth Beyond COVID Glory?
Pfizer engineers a “diversified oncology fortress” strategy featuring 108 pipeline candidates (one-third new molecular entities) across oncology, rare diseases, vaccines,…
